期刊
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
卷 26, 期 1, 页码 49-56出版社
KARGER
DOI: 10.1159/000315105
关键词
Multiple Sclerosis; Sphingolipids; Ceramide; Sphingomyelinase; Sphingomyelin; Sphingosine; Sphingosine-1-phosphate; Gangliosides
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system, mainly affecting young adults. Current therapeutic approaches focus on the suppression of the immune system and on blockade of T cell blood-brain barrier transmigration into the brain parenchyma. Recently, sphingolipids that have been linked to MS pathophysiology, i.e., Sphingosine-1-phosphate (S1P), intracellularly produced lysophospholipids, can be recognized by receptors located on T and B cells. The recent demonstration that S1P is able to direct lymphocyte trafficking between blood and lymphoid system has been translated into therapeutic application: A S1P analogue, FTY720, is currently under clinical investigation in MS. Further cell membrane lipids that are involved in cell proliferation, signalling cascades and apoptosis might be of relevance in MS pathophysiology and, thus, await further investigation. This review focuses on the current knowledge on the role of sphingolipids in MS and discusses their potential therapeutical implications. Copyright (C) 2010 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据